Immune cell-derived membrane nanovesicles: A promethean fire for autoimmune disease therapy through immune cell mimicry.

What To Know

The review reports that IACMVs are membrane vesicles produced from immune or blood cells (macrophages, dendritic cells, neutrophils, platelets, red blood cells) that can be engineered to deliver drugs, peptides, or nucleic acids and may target sites of inflammation because they retain parent-cell surface markers.

Authors discuss potential applications across multiple autoimmune diseases, explicitly listing inflammatory bowel disease among conditions where IACMVs have been explored preclinically or conceptually. The paper focuses on preparation methods, mechanisms of action, and translational barriers rather than reporting new clinical trial results.

Key translational challenges noted include manufacturing scale-up, preserving membrane integrity and function, avoiding unintended immune responses, and achieving efficient and stable cargo loading—issues that could affect timing and feasibility of human treatments.